Skip to main content
SpringerLink
Log in

Bimatoprost

  • Chapter
  • First Online:
Androgenetic Alopecia From A to Z

  • 564 Accesses

Abstract

Bimatoprost (Lumigan®, Allergan Inc., Irvine, CA) is a synthetic analog of prostamide and prostaglandin. It was initially developed to reduce intraocular pressure (IOP) in glaucoma by increasing the outflow of aqueous humor through both the trabecular meshwork and the uveoscleral route [1–4]. Bimatoprost is stereo-chemically similar to other prostaglandin-F2α (PGF2α) analogs, including Latanoprost, Travoprost, and Unoprostone. The only chemical difference is that Bimatoprost has an ethyl amide instead of an isopropyl-ester on the C-1 carbon of the α-chain [5]. Lumigan® ophthalmic solution containing Bimatoprost 0.03%, was approved by the FDA in 2001 for the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma [6]. It is considered as the most potent and effective anti-glaucoma agent [7]. Its safety and efficacy in the reduction of IOP have been well documented in clinical trials lasting up to 4 years, as well as extensive clinical experience totaling >9 million patient-years of exposure [8].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, Vandenburgh AM. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131(1):19–24.

    CAS  PubMed  Google Scholar 

  2. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S337–45.

    PubMed  Google Scholar 

  3. Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol Ther. 2008;120(1):71–80.

    CAS  PubMed  Google Scholar 

  4. Krauss AH, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49(Suppl 1):S5–11.

    PubMed  Google Scholar 

  5. Woodward DF, Phelps RL, Krauss AH, et al. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev. 2004;22(2):103–20.

    CAS  PubMed  Google Scholar 

  6. Lumigan [package insert]. Irvine, CA: Allergan, Inc.; 2006

    Google Scholar 

  7. Woodward DF, Liang Y, Krauss AH. Prostamides (prostaglandin-ethanolamides) and their pharmacology. Br J Pharmacol. 2008;153(3):410–9.

    CAS  PubMed  Google Scholar 

  8. Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL, Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008;92(10):1387–92.

    CAS  PubMed  Google Scholar 

  9. Woodward DF, Krauss AH, Chen J, Liang Y, et al. Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther. 2003;305(2):772–85.

    CAS  PubMed  Google Scholar 

  10. Elias MJ, Weiss J, Weiss E. Bimatoprost ophthalmic solution 0.03% for eyebrow growth. Dermatol Surg. 2011;37(7):1057–9.

    CAS  PubMed  Google Scholar 

  11. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):544–7.

    CAS  PubMed  Google Scholar 

  12. Sugimoto M, Sugimoto M, Uji Y. Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol. 2002;37(6):342–5.

    PubMed  Google Scholar 

  13. Chiba T, Kashiwagi K, Ishijima K, Furuichi M, Kogure S, Abe K, Chiba N, Tsukahara S. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004;48(2):141–7.

    CAS  PubMed  Google Scholar 

  14. Elgin U, Batman A, Berker N, Ilhan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol. 2006;16(2):247–50.

    CAS  PubMed  Google Scholar 

  15. Uno H, Zimbric ML, Albert DM, Stjernschantz J. Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: a pilot study. Acta Derm Venereol. 2002;82(1):7–12.

    CAS  PubMed  Google Scholar 

  16. Mansberger SL, Cioffi GA. Eyelash formation secondary to latanoprost treatment in a patient with alopecia. Arch Ophthalmol. 2000;118(5):718–9.

    CAS  PubMed  Google Scholar 

  17. Michelet JF, Commo S, Billoni N, Mahé YF, Bernard BA. Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect. J Invest Dermatol. 1997;108(2):205–9.

    CAS  PubMed  Google Scholar 

  18. Cohen JL. Commentary: from serendipity to pilot study and then pivotal trial: Bimatoprost topical for eyelash growth. Dermatol Surg. 2010;36(5):650–1.

    CAS  PubMed  Google Scholar 

  19. Woodson SA. Latisse: Empirical discovery yields treatment for sparse eyelashes. Nurs Womens Health. 2009;13(3):243–8.

    PubMed  Google Scholar 

  20. Higginbotham EJ, Schuman JS, Goldberg I, Gross RL, Van Denburgh AM, Chen K, Whitcup SM, Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120(10):1286–93.

    CAS  PubMed  Google Scholar 

  21. Dubey AK. An effect of bimatoprost: adverse for some, therapeutic for others. Int J Trichol. 2011;3(2):129–30.

    Google Scholar 

  22. Tosti A, Pazzaglia M, Voudouris S, Tosti G. Hypertrichosis of the eyelashes caused by bimatoprost. J Am Acad Dermatol. 2004;51(5 Suppl):S149–50. Erratum in: J Am Acad Dermatol. 2004 51(6):104046

    PubMed  Google Scholar 

  23. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis. Clin Ophthalmol. 2010;4:349–58.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004;12(8):543–9.

    PubMed  Google Scholar 

  25. Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 2010;117(5):1024–31.

    PubMed  Google Scholar 

  26. Rundle RL. Drug that lengthens eyelashes sets off flutter. Wall Street J. 2007:B1 http://online.wsj.com/article/SB119543055372597359.html. Accessed 26 May 2009.

  27. MSNBC. MSNBC: FDA seizes $two million of potentially harmful SJ eye product KNTV-TV 2:44 p.m. ET, Sat., Nov. 17, 2007; 2007. http://www.lipotreatmentfacts.org/downloads/WiredScienceBlog_11-2007.pdf. Accessed 22 June 2009.

  28. Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010;36(9):1361–71.

    CAS  PubMed  Google Scholar 

  29. Sharif NA, Williams GW, Kelly CR. Bimatoprost and its free acid are prostaglandin FP receptor agonists. Eur J Pharmacol. 2001;432(2–3):211–3.

    CAS  PubMed  Google Scholar 

  30. Johnstone MA, Albert DM. Prostaglandin-induced hair growth. Surv Ophthalmol. 2002;47(Suppl. 1):S185–202.

    PubMed  Google Scholar 

  31. Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E. Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost. Br J Dermatol. 2010;162(6):1186–97.

    CAS  PubMed  Google Scholar 

  32. Choi YM, Diehl J, Levins PC. Promising alternative clinical uses of prostaglandin F2α analogs: beyond the eyelashes. J Am Acad Dermatol. 2015;72(4):712–6.

    CAS  PubMed  Google Scholar 

  33. Smith S, Fagien S, Whitcup SM, Ledon F, Somogyi C, Weng E, Beddingfield FC 3rd. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol. 2012;66(5):801–6.

    CAS  PubMed  Google Scholar 

  34. Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg. 2010;36(5):638–49.

    CAS  PubMed  Google Scholar 

  35. Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol. 2010;9(2):96–102.

    PubMed  Google Scholar 

  36. Modschiedler K, von den Driesch P, Paus R. Hyperpigmentosis and hypertrichosis of the eyelids after use of bimatoprost eye drops. J Dtsch Dermatol Ges. 2005;3(4):276–7.

    PubMed  Google Scholar 

  37. Galloway GD, Eke T, Broadway DC. Periocular cutaneous pigmentary changes associated with bimatoprost use. Arch Ophthalmol. 2005;123(11):1609–10.

    PubMed  Google Scholar 

  38. Stjernschantz JW, Albert DM, Hu DN, Drago F, Wistrand PJ. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(Suppl. 1):S162–75.

    PubMed  Google Scholar 

  39. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022369_latisse_toc.cfm.

  40. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM, Bimatoprost/Latanoprost Study Group. A six month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135(1):55–63.

    CAS  PubMed  Google Scholar 

  41. Gandolfi S, Simmons ST, Sturm R, Chen K, Van Denburgh AM, Bimatoprost Study Group 3. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18(3):110–21.

    CAS  PubMed  Google Scholar 

  42. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(Suppl. 1):S105–15.

    PubMed  Google Scholar 

  43. Gupta AK, Carviel J, Abramovits W. Treating alopecia areata: current practices versus new directions. Am J Clin Dermatol. 2017;18(1):67–75.

    PubMed  Google Scholar 

  44. Zaher H, Gawdat HI, Hegazy RA, Hassan M. Bimatoprost versus mometasone furoate in the treatment of scalp alopecia areata: a pilot study. Dermatology. 2015;230(4):308–13.

    CAS  PubMed  Google Scholar 

  45. Li AW, Antaya RJ. Successful treatment of pediatric alopecia areata of the scalp using topical Bimatoprost. Pediatr Dermatol. 2016;33(5):e282–3.

    PubMed  Google Scholar 

  46. Emer JJ, Stevenson ML, Markowitz O. Novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution. J Drugs Dermatol. 2011;10(7):795–8.

    PubMed  Google Scholar 

  47. Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515–22.

    PubMed  Google Scholar 

  48. Allergan. Safety and pharmacokinetics study of new formulation of bimatoprost in patients with alopecia; 2013. https://clinicaltrials.gov/ct2/show/NCT01189279. NLM identifier: NCT01189279.

  49. Duke University. Topical bimatoprost effect on androgen dependent hair follicles; 2011. https://clinicaltrials.gov/ct2/show/NCT02170662

  50. Allergan. Safety and efficacy study of bimatoprost in the treatment of men with androgenic alopecia; 2012. https://clinicaltrials.gov/ct2/show/NCT01325337

  51. Allergan. A safety and efficacy study of bimatoprost in men with androgenic alopecia (AGA); 2016. https://clinicaltrials.gov/ct2/show/NCT01904721. NLM Identifier: NCT01904721

  52. Allergan. Safety and efficacy study of bimatoprost in the treatment of women with female pattern hair loss; 2012. https://clinicaltrials.gov/ct2/show/NCT01325350

  53. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–7.

    PubMed  Google Scholar 

  54. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men—short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22.

    CAS  PubMed  Google Scholar 

  55. Carrillo MM, Nicolela MT. Cystoid macular edema in a low-risk patient after switching from latanoprost to bimatoprost. Am J Ophthalmol. 2004;137(5):966–8.

    PubMed  Google Scholar 

  56. Herane M, Urbina F. Topical prostaglandin F(2alpha) analog induced poliosis. Am J Ophthalmol. 2004;137(5):965–6.

    Google Scholar 

  57. Packer M, Fine IH, Hoffman RS. Bilateral nongranulomatous anterior uveitis associated with bimatoprost. J Cataract Refract Surg. 2003;29(11):2242–3.

    PubMed  Google Scholar 

  58. Stewart WC, Stewart JA, Jenkins JN, Jackson AL. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J Glaucoma. 2003;12(6):475–9.

    PubMed  Google Scholar 

  59. Brandt JD, VanDenburgh AM, Chen K, Whitcup SM, Bimatoprost Study Group. Comparison of once or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology. 2001;108(6):1023–31. discussion 1032

    CAS  PubMed  Google Scholar 

  60. Laibovitz RA, VanDenburgh AM, Felix C, David R, Batoosingh A, Rosenthal A, Cheetham J. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management. Arch Ophthalmol. 2001;119(7):994–1000.

    CAS  PubMed  Google Scholar 

  61. DuBiner H, Cooke D, Dirks M, Stewart WC, Van Denburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45(Suppl. 4):S353–60.

    PubMed  Google Scholar 

  62. Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ. 2001;323(7316):783.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998;32(4):504–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Athens, Attiki, Greece

    Konstantinos Anastassakis

Authors
  1. Konstantinos Anastassakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anastassakis, K. (2022). Bimatoprost. In: Androgenetic Alopecia From A to Z . Springer, Cham. https://doi.org/10.1007/978-3-031-08057-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-08057-9_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-08056-2

  • Online ISBN: 978-3-031-08057-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation